Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

November 30, 2010

Conditions

Typhoid Fever

Interventions

BIOLOGICAL

Typherix

1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide

BIOLOGICAL

NVGH Vi-CRM197

1 dose of 0.5 mL containing 25 mcg of Vi-CRM

Trial Locations (1)

Center for the Evaluation of Vaccination (CEV), Antwerp